# Building an Ecosystem to Drive innovation

Dedicated to accelerating the development of new cancer treatment

Oslo Cancer cluster

- Leading innovation cluster
  - Centrally positioned and connected to global industry
  - ECEI GOLD Label "Excel in Cluster Excellence"
- Award-winning Incubator
  - > 30 start-ups / companies
  - Successful financing / IPO
  - EU / national program award
- International cooperation
  - EU projects funded / mediated funding
  - Strong US / EU network
- National genetics and precision medicine
  - Connect repurposing project initiator and coordinator

MEMBERS OF OSLO CANCER CLUSTER

https://www.oslocancercluster.no

OSLO CANCER CLUSTER - A HISTORY ABOUT PUBLIC PRIVATE PARTNERSHIP

Norwegian Cancer Registry

DNR Research Foundation

New ICR Building

1932

1953

2006

2015

1952

1987

2009

2019

Norwegian Radium Hospital

Institute for Cancer Research (ICR)

Oslo Cancer Cluster

OCC Innovation Park
Diagnostic Laboratories
Cancer Registry, Incubator

Oslo University Hospital new Clinic building and Proton center initiated

OSLO CANCER CLUSTER

NCE Norwegian Centres of Expertise

OCC is a place for networking and building bridges through the whole value chain

Strategy and goals in brief, 2020-2022

Facilitator: advancing a dynamic innovation ecosystem where companies, investors, academic researchers, clinicians and patients collaborate.

Ambassador: connecting Norwegian innovators to global value chains, international investors and partners in academia and industry.

Changemaker: improving the framework conditions for cancer innovations in the Norwegian health industry and raising expertise.

Advancing the onconolgy innovation ecosystem

International Cancer Cluster Showcase 2022

Digital Brochure - Launched June 13, 2022

Cambridge Innovation Partners

MONTRÉAL INVIVO

THE WISTAR INSTITUTE

OSLO CANCER CLUSTER

obn

biopôle

MATWIN

School collaboration – integrated

Projects connect students with research and business

SPARK NORWAY: ADVANCING ACADEMIC INNOVATION IN SPARK GLOBAL NETWORK

OSLO CANCER CLUSTER INCUBATOR PROGRAM
Hands-on coaching to make start-ups investable

- Developing novel cancer therapies for the benefit of patients and avoiding the traps on the way

- 35 members: start-ups, global pharma, investors, IT companies, lawyer, TTO, academic groups, CROs

- 5.000 m^2 offices and labs embedded in Comprehensive Cancer Center Campus with University Hospital, Cancer Registry, Biobanks, Clinical Trial Unit and Institute for Cancer Research

OSLO CANCER CLUSTER
INCUBATOR

A GROWING PIPELINE: STRONG IN CANCER IMMUNOTHERAPY

Global investors important

OSLO CANCER CLUSTER

ABOUT US   MEMBER

You are here: Home / N

Else Marit Inderberg and Sébastien Wälchli often work in one of the cell labs in Oslo Cancer Cluster Incubator. Photo: Christopher Olssøn

How Cancer Research Becomes a Company

Thursday, July 6, 2017 / by oslocancer

The Department of Cellular Therapy is great at transforming cancer research into new companies. The latest spin-out is Zelluna.

SHIFTER   Shifter +   Nyhetsbrev   Annonsere   Stillinger   Abonner   Logg inn

OncoImmunity solgt til NEC. Investeringsdirektør Anders Tuv (t.v.) har vært sentral i utviklingen sammen med gründerne Richard Stratford og Trevor Clancy (t.h.). Foto: Radforsk/Oslo Cancer Cluster

Japansk gigant kjøper norsk AI-startup: Leder vei i kampen mot kreft

Per-Ivar Nikolaisen
Redaktør og gründer i Shifter

New technology shape the industry

Bruker kunstig intelligens i jakten på kreftsvulster

Forskningsprosjektet som blir lansert av DoMore Diagnostics har mottatt 15 millioner i fersk kapital fra storfondet Norselab og teknologiinvestor Øyvind Grotmol.

AI colorectal cancer diagnostics receives CE-IVD mark

15 JUNE 2022 09:48

f Share

DoMore Diagnostics, a developer of pathology AI algorithms, has achieved CE-IVD mark for the Histotype Px Colorectal, a deep learning algorithm that predict patient outcome based on analysis of digital histology images.

The product uses artificial intelligence to predict patient outcome based on advanced image analysis. Histotype Px Colorectal builds on the research led by Institute for Cancer Genetics and Informatics at Oslo University Hospital, and the deep learning algorithm is trained on and developed with close to 100 million image tiles. The analysis is conducted on high resolution scans from standard H&E stained slides providing shorter turnaround times.

Oslo Cancer Cluster Innovation park Phase 2 – Public and private, offices and laboratories

Phase 3 Oslo Science Hub – International pharma/diagnostics for precision medicine

The start of Oslo Science City

Oslo University Hospital
Norwegian Radium Hospital

- New Clinic Building
- New Proton Center ++

OSLO CANCER CLUSTER INNOVATION PARK

Phase 2 Offices/ Labs

OSLO CANCER CLUSTER INNOVATION PARK

OSLO CANCER CLUSTER INNOVATION PARK

Phase 3 Incl. pharma/ diagnostics/ labservices